Daiichi Sankyo RD Novare

Daiichi Sankyo RD Novare is a specialized research and development subsidiary of the global pharmaceutical company Daiichi Sankyo. Established in 2011 and headquartered in Tokyo, the company functions as the primary engine for the group's drug discovery and research support services. Its expertise spans medicinal chemistry, biological evaluation, pharmacokinetics, and safety assessment, with a heavy focus on the development of innovative oncology treatments. RD Novare is instrumental in advancing Daiichi Sankyo's proprietary DXd Antibody-Drug Conjugate (ADC) technology platform, which has produced several breakthrough therapies. The company provides end-to-end R&D support, from early-stage target identification to CMC research and clinical trial logistics. By integrating diverse research functions, RD Novare accelerates the delivery of novel medicines to patients worldwide.